Racura Oncology has secured $34.3 million following a series of fundraising initiatives supported by new and existing shareholders, giving the company a strong cash balance to fully fund its RC220 clinical programs in Acute Myeloid Leukaemia, EGFRm non-small cell lung cancer and anthracycline cardioprotection in solid tumour patients. …
Racura completes significant fund raise to advance three clinical trials
June 17, 2026 Australian Biotech
Latest Video
New Stories
-
Illumina taps medtech leader to head Australia and New Zealand operations
July 8, 2026 - - Latest News -
PYC Therapeutics names Thomas Ulmer as new chief financial officer
July 8, 2026 - - Australian Biotech -
In a perfect world, the minister would not be in this position, and he might question the timeline
July 8, 2026 - - Latest News -
Aegros completes Australia’s second large scale plasma fractionation plant
July 8, 2026 - - Latest News -
'But I've said it's really important that these two drugs stay on the PBS'
July 7, 2026 - - Latest News -
Just another attempt to create a new excuse to avoid a meaningful discussion about change
July 7, 2026 - - Latest News -
Australia must keep development manufacturing and jobs here to secure health and economic benefits
July 7, 2026 - - Latest News